Statins and biomarkers of inflammation

Sridevi Devaraj, Jason Rogers, Ishwarlal Jialal

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalCurrent Atherosclerosis Reports
Volume9
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Biomarkers
Inflammation
C-Reactive Protein
Atherosclerosis
Anti-Inflammatory Agents
Cholesterol
Clinical Trials
LDL Cholesterol
Epidemiologic Studies
Oxidoreductases
Blood Platelets
Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statins and biomarkers of inflammation. / Devaraj, Sridevi; Rogers, Jason; Jialal, Ishwarlal.

In: Current Atherosclerosis Reports, Vol. 9, No. 1, 01.2007, p. 33-41.

Research output: Contribution to journalArticle

Devaraj, S, Rogers, J & Jialal, I 2007, 'Statins and biomarkers of inflammation', Current Atherosclerosis Reports, vol. 9, no. 1, pp. 33-41. https://doi.org/10.1007/BF02693938
Devaraj, Sridevi ; Rogers, Jason ; Jialal, Ishwarlal. / Statins and biomarkers of inflammation. In: Current Atherosclerosis Reports. 2007 ; Vol. 9, No. 1. pp. 33-41.
@article{57a76200c0a6453bab5204a454d23953,
title = "Statins and biomarkers of inflammation",
abstract = "Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins.",
author = "Sridevi Devaraj and Jason Rogers and Ishwarlal Jialal",
year = "2007",
month = "1",
doi = "10.1007/BF02693938",
language = "English (US)",
volume = "9",
pages = "33--41",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Statins and biomarkers of inflammation

AU - Devaraj, Sridevi

AU - Rogers, Jason

AU - Jialal, Ishwarlal

PY - 2007/1

Y1 - 2007/1

N2 - Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins.

AB - Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins.

UR - http://www.scopus.com/inward/record.url?scp=33846157745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846157745&partnerID=8YFLogxK

U2 - 10.1007/BF02693938

DO - 10.1007/BF02693938

M3 - Article

C2 - 17169243

AN - SCOPUS:33846157745

VL - 9

SP - 33

EP - 41

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -